Rising healthcare costs, coupled with high-profile stories of price gouging at some small pharmaceutical companies, have left consumers feeling ripped off
Total medicine spending surged to $424.8 billion in 2015, representing an increase of 12.2%. Here's why that growth figure is closer to 2.9%.
Pearson expected to say price hikes were too aggressive; Collegium's painkiller receives full FDA approval; most hospitals stop advertising infant formula
When pharmaceutical companies are needed, we're Jonas Salks; when we ask to be paid, we're Martin Shkrelis.
Government identifies barriers to eliminating hepatitis C; Pearson agrees to congressional deposition; CMS reportedly plans to revoke Theranos license
California bill would require price disclosures; AbbVie's and Genentech's blood-cancer drug is approved; FDA expands metformin use
The drugmaker instead suggested using an economic model it developed.
GSK won't patent drugs sold in low-income countries; experimental dermatitis therapy met Phase III endpoints; the FDA issues biosimilar labeling guidance
The American College of Physicians questioned the role direct-to-consumer advertising plays in contributing to prescription drug costs.
Pearson to be replaced at Valeant; Pfizer's Xeljanz meets Phase III goals; Harvard partners with Merck on leukemia drug development
OptumRx partners with Walgreens Boots Alliance; Turing's former lawyer said Daraprim price hike was unjustified; the White House names moonshot leader
Exactly how does the erosion of public trust in the goodwill of the pharma industry impact the work being done to raise awareness and also market medicines? It's hard to tell, so far.
We need to consider that not every expenditure is beneficial to patients: perhaps that Super Bowl commercial or that sales meeting in Maui may not be in their best interest.
Providing financial assistance to patients has become a common refrain in drugmakers' defense of high-priced drugs.
Aegerion slashes workforce; GSK president says downward pressure on drug prices is here to stay; Novartis acquires European rights to Remicade biosimilar
A House lawmaker called pricing strategies used by Turing and Valeant "repulsive."
Valeant to push for changes to financial-assistance rules; House to hold hearing on drug-pricing practices; FDA committee says Lundbeck can add information to leaflet
We look forward to collaborating with stakeholders across the healthcare system—including PBMs—to extend success to disease states beyond hepatitis C, writes PhRMA CEO Stephen Ubl.
The formula's pretty simple: Be sure you can defend your drug's value proposition, without blushing, says BioPharma Alliance's Mike Luby.
Prior to Medicines360's arrival on the scene, there were only three IUDs on the market. The lack of competition drove prices sky-high.
Part of drugmakers' sales growth stems from price increases; AbbVie's Venetoclax gets second Breakthrough designation; two states in India stop Avastin sales
Government pressure can influence drug-pricing decisions; Samsung's biosimilar version of Enbrel is approved in Europe; J&J to cut jobs in medical-devices business
Valeant is "uncertain" when CEO will return; Bayer hires Razorfish and iCrossing for digital; more drugmakers that sell hemophilia drugs are hiring patients
Drug pricing is easily the biggest controversy but pharma faced other issues, too, like the AMA's call to ban DTC advertising.
The firm began working with the pharma company before outrage over its drug pricing but has more recently supported the client after former CEO Martin Shkreli was arrested.
With the huge advances in treatment comes a raft of concerns, among them daunting pricing pressures.
Shkreli resigns from Turing; Keytruda approved as first-line melanoma treatment; drugmakers seek to fend off California pricing ballot initiative
Britain says Bristol-Myers Squibb's Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials
Physicians complain about price of Lilly's new cancer drug; AstraZeneca considers acquisition of Acerta Pharma; Shkreli plans to raise price of another old drug
UnitedHealth gives Praluent preferred status on its formularies; Stat News examines the first DTC drug ad; Britain to cover Entresto
Click here to learn about the Agency Issue.